Andrée-Laure Herr

Learn More
Unrelated umbilical cord blood (UCB) has been widely used to treat patients lacking a well-matched HLA donor. Cell dose is a critical determinant of outcomes in cord blood transplantation, limiting the use of this strategy for low body weight patients. To overcome this limitation, infusion of two partially HLA-matched cord units was adopted as a new(More)
To describe the incidence, risk factors, and treatment of autoimmune diseases (ADs) occurring after cord blood transplantation (CBT), we analyzed both CBT recipients reported to EUROCORD who had developed at least 1 new AD and those who had not. Fifty-two of 726 reported patients developed at least 1 AD within 212 days (range, 27-4267) after CBT. Cumulative(More)
We analyzed risk factors influencing outcomes after related (R) human leukocyte antigen-identical cord blood transplantation (CBT) for 147 patients with malignancies reported to Eurocord-European Group for Blood and Marrow Transplantation. CBT has been performed since 1990; median follow-up was 6.7 years. Median patient age was 5 years. Acute leukemia was(More)
BACKGROUND Bone complications after hematopoietic stem-cell transplantation (HSCT) are relatively frequent. Evaluation of biomarkers of bone turnover and dual energy x-ray absorptiometry (DEXA) are not known in this context. METHODS We prospectively evaluated bone mineral density, biomarkers of bone turnover, and the cumulative incidence of bone(More)
1Eurocord, Hôpital Saint-Louis, Paris, France; 2Hospital de Clinicas, Curitiba, Brazil; 3IRCCS Ospedale Bambino Gesù, Rome, University of Pavia, Pavia, Italy; 4Royal Children’s Hospital, Melbourne, Australia; 5Leiden University Medical Center, Leiden, The Netherlands; 6Hôpital Claude Huriez, Lille, France; 7Clinica di Oncoematologia Pediatrica, Padova,(More)
  • 1